Overview

Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Status:
Completed

Trial end date:
2009-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy of rabeprazole extended release (ER) 50 mg (once daily) versus ranitidine 150 mg (twice daily) in the maintenance of complete healing in subjects with healed erosive gastroesophageal reflux disease (eGERD).

Phase:

Phase 3

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Rabeprazole
Ranitidine
Ranitidine bismuth citrate